N	Concordance
1	e patient should be treated as having a nonseminoma, even though the pathologic 
2	r is broadly divided  into seminoma and nonseminoma types for treatment planning
3	 fetoprotein (AFP) should be treated as nonseminomas. Elevation of the beta sub
4	ance has been used for selected stage I nonseminoma patients. This strategy avoi
5	tial chemotherapy with regimens used in nonseminoma testis cancer is also very 
6	  serum markers; 3) primary mediastinal nonseminoma; and 4) large number of lung
7	gt;/= 1.5 x N and </= 10 x N  28% of nonseminomas 5 year PFS 75% 5 year sur
8	as compared with the radioresistance of nonseminomas. Radiation therapy to the l
9	tage seminomas or RPLND for early-stage nonseminomas. Modifications in the surgi
10	in a proportion of the undifferentiated nonseminomas. This differential pattern 
11	seous) are more common in patients with nonseminomas than in patients with semin